RayzeBio
RayzeBio is a clinical-stage radiopharmaceutical therapeutics (RPT) oncology company developing targeted alpha-emitter therapies, primarily using actinium-225 (225Ac), to treat solid tumors. Its lead program, RYZ101 (225Ac-DOTATATE), targets somatostatin receptor 2 (SSTR2) which is over-expressed in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and extensive-stage small cell lung cancer (ES-SCLC). The company was founded in 2020 in San Diego, went public on Nasdaq in September 2023 (ticker RYZB), and was acquired by Bristol Myers Squibb in February 2024 for approximately $4.1 billion.
Public Company
RayzeBio is publicly traded
IPO'd on September 15, 2023
This company is no longer available on our private secondary market. Shares can be traded publicly under RYZB.
Overview
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2020
Employees
51–200
Total Funding
$426M
4 rounds
Funding
Total raised $426M across 4 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 05-09-2026
Latest Round
Type
Series D
Date
August 25, 2022
Amount
$168M
Valuation
—
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| August 25, 2022 | Series D | $168M | — | Viking Global Investors, Sofinnova Investments, Wellington Management |
| June 2021 | Series C | $108M | — | |
| December 2020 | Series B | $105M | — | Venrock Healthcare Capital Partners |
Leadership
Ken Song
President and CEO
Deborah Charych
Co-Founder and Chief Technology Officer
Aaron Kantoff
Co-Founder
Aron Knickerbocker
Co-Founder
Arvind Kush
Chief Financial Officer
Aubrey Haddach
General Counsel
Competitors
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Novartis (Advanced Accelerator Applications)
Pharma leader in radioligand therapy with marketed products Pluvicto (177Lu-PSMA-617) for prostate cancer and Lutathera (177Lu-DOTATATE) for GEP-NETs.
Point Biopharma
Radiopharmaceutical oncology company developing targeted radioligand therapies; acquired by Eli Lilly in December 2023 for ~$1.4B.
Fusion Pharmaceuticals
Clinical-stage radiopharmaceutical company focused on actinium-225 targeted alpha therapies for solid tumors; acquired by AstraZeneca in 2024.
Lantheus Holdings
Diagnostic and therapeutic radiopharmaceutical company; markets Pylarify and is building a targeted radiotherapy pipeline.
Telix Pharmaceuticals
Australia-based commercial-stage radiopharmaceutical oncology and rare disease company developing diagnostic and therapeutic radioligands.
Clovis Oncology (FAP-2286 program)
Developer of targeted radiopharmaceutical FAP-2286 (now under Novartis) targeting fibroblast activation protein for solid tumors.
RayzeBio Investment FAQ
RayzeBio FAQ
Yes, RayzeBio is publicly traded under the ticker symbol RYZB on the Nasdaq. The company went public in September 15, 2023.
RayzeBio trades under the ticker symbol RYZB on the Nasdaq. It began trading in September 15, 2023.
RayzeBio (RYZB on the Nasdaq) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker RYZB to place an order.
RayzeBio went public in September 15, 2023 via ipo. RayzeBio completed its IPO on Nasdaq (ticker RYZB) on September 15, 2023, raising approximately $358M at $18 per share. Just over three months later, on December 26, 2023, Bristol Myers Squibb announced a definitive agreement to acquire RayzeBio for $62.50 per share, or approximately $4.1B equity value (~$3.6B net of cash). The acquisition closed on February 26, 2024, with RayzeBio becoming a wholly owned subsidiary of BMS and shares ceasing to trade on Nasdaq.
RayzeBio raised $426M across 4 disclosed funding rounds prior to its public listing.
RayzeBio was co-founded by Deborah Charych, Aaron Kantoff, and Aron Knickerbocker in 2020.
RayzeBio is headquartered in San Diego, CA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.